China Opens Licensed Access Pathway to Approved Stem-Cell and Gene Therapies at Boao Lecheng Pilot Zone
Verified China Care highlights the licensed clinical-translation pathway at China's Boao Lecheng pilot zone, where 21 stem-cell and gene-therapy projects are approved, with published prices and medical-visa routes for international patients.
NEWARK, Del. — August 31, 2026 — Verified China Care, a U.S.-based medical travel coordinator connecting international patients with accredited hospitals in China, today highlighted the opening of a regulated access pathway at the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China, where 21 stem-cell and gene-therapy projects have been approved for clinical translation and application since March 2025.
Across five approval batches between March 2025 and March 2026, the pilot zone has cleared 21 projects spanning cell therapies, gene therapy, and cell vaccines. More than 300 patients have been treated, and published per-treatment prices range from 16,000 to 480,000 yuan (approximately US$2,200 to US$67,000). The approved list includes umbilical cord mesenchymal stem cells for knee osteoarthritis, airway basal stem cells for COPD, RPE65 gene therapy (AAV) for retinal dystrophy, and umbilical cord mesenchymal stem cells for type 2 diabetes at 58,000 yuan per injection — a three-injection course of approximately US$24,400.
The pathway sits inside a national regulatory framework. In October 2025, China's State Council issued the Regulations on the Administration of Clinical Study and Clinical Translation and Application of New Biomedical Technologies (Order No. 818), in force since May 1, 2026, which formalize a dual-track system: product registration for drugs and devices on one track, and clinical translation and application of new technologies on the other. Hainan's pilot regulations were adopted in November 2024, with implementation measures issued in January 2025 that designated Boao Lecheng as the zone for translating new biomedical technologies into clinical care.
These approvals operate on the pilot zone's clinical translation track and are distinct from national NMPA marketing approvals. As of 2026, for example, no stem-cell diabetes product holds NMPA marketing approval — the Boao pathway is a separate, licensed track. For international patients, the zone offers a regulated route supported by medical visa options (S1/S2), Hainan's visa-free entry framework covering citizens of 86 countries, and pilot hospitals that run international departments with English-speaking coordinators.
Team VCC, the coordination team behind Verified China Care, commented: "As China's licensed pathway for advanced therapies takes shape, international patients deserve a way to evaluate it that is transparent, verified, and financially protected. The Boao pathway is significant because it is licensed and price-published. Our role is to help patients navigate it safely — verifying hospital credentials, coordinating logistics, and protecting payments through escrow."
Verified China Care coordinates with JCI-accredited and CIHA-equivalent hospitals, publishes all-in pricing that itemizes what is included, and structures payments through an independent escrow agent, released in stages tied to documented treatment milestones. The company is currently helping international patients understand and evaluate the Boao pathway as part of its broader medical-travel coordination work.
About Verified China Care — Verified China Care (verifiedchinacare.com) is a U.S.-based medical travel coordinator connecting international patients with accredited hospitals in China. The company publishes transparent all-in pricing, verifies hospital credentials and accreditation status, and protects patient payments through third-party escrow released at documented treatment milestones.
Media contact: [email protected] · verifiedchinacare.com · +1 302 217 0438
Across five approval batches between March 2025 and March 2026, the pilot zone has cleared 21 projects spanning cell therapies, gene therapy, and cell vaccines. More than 300 patients have been treated, and published per-treatment prices range from 16,000 to 480,000 yuan (approximately US$2,200 to US$67,000). The approved list includes umbilical cord mesenchymal stem cells for knee osteoarthritis, airway basal stem cells for COPD, RPE65 gene therapy (AAV) for retinal dystrophy, and umbilical cord mesenchymal stem cells for type 2 diabetes at 58,000 yuan per injection — a three-injection course of approximately US$24,400.
The pathway sits inside a national regulatory framework. In October 2025, China's State Council issued the Regulations on the Administration of Clinical Study and Clinical Translation and Application of New Biomedical Technologies (Order No. 818), in force since May 1, 2026, which formalize a dual-track system: product registration for drugs and devices on one track, and clinical translation and application of new technologies on the other. Hainan's pilot regulations were adopted in November 2024, with implementation measures issued in January 2025 that designated Boao Lecheng as the zone for translating new biomedical technologies into clinical care.
These approvals operate on the pilot zone's clinical translation track and are distinct from national NMPA marketing approvals. As of 2026, for example, no stem-cell diabetes product holds NMPA marketing approval — the Boao pathway is a separate, licensed track. For international patients, the zone offers a regulated route supported by medical visa options (S1/S2), Hainan's visa-free entry framework covering citizens of 86 countries, and pilot hospitals that run international departments with English-speaking coordinators.
Team VCC, the coordination team behind Verified China Care, commented: "As China's licensed pathway for advanced therapies takes shape, international patients deserve a way to evaluate it that is transparent, verified, and financially protected. The Boao pathway is significant because it is licensed and price-published. Our role is to help patients navigate it safely — verifying hospital credentials, coordinating logistics, and protecting payments through escrow."
Verified China Care coordinates with JCI-accredited and CIHA-equivalent hospitals, publishes all-in pricing that itemizes what is included, and structures payments through an independent escrow agent, released in stages tied to documented treatment milestones. The company is currently helping international patients understand and evaluate the Boao pathway as part of its broader medical-travel coordination work.
About Verified China Care — Verified China Care (verifiedchinacare.com) is a U.S.-based medical travel coordinator connecting international patients with accredited hospitals in China. The company publishes transparent all-in pricing, verifies hospital credentials and accreditation status, and protects patient payments through third-party escrow released at documented treatment milestones.
Media contact: [email protected] · verifiedchinacare.com · +1 302 217 0438
- Contact Email
- [email protected]
- Issued By
- Team VCC
- Phone
- +1 302 217 0438
- Business Address
- 131 Continental Dr, Suite 305
Newark, DE 19713, USA - Country
- United States
- Categories
- Biotech · Health · Healthcare
- Last Updated
- August 31, 2026